MedImmune news from FiercePharma
NewsAstraZeneca launches $790M in Euro bonds
AstraZeneca is issuing more bonds to pay off its MedImmune debts. This time, it's an 18-month European issue to the tune of about $790 million; the bonds will be sold to institutions outside the U.S. Read more...
ALSO NOTED: Canada OKs Lucentis reimbursement; Coated stents better after heart attack;
> In a reversal, Canadian regulators ordered provinces to pay for Lucentis, the Genentech macular degeneration drug that has come under fire for its high price tag. Read more...
ALSO NOTED: MedImmune appoints new SVP; Merck drug gets HealthCanada nod;
> MedImmune shuffled its management team last week: Andrew Skibo joined the company as senior vice president for engineering, and Dr. JoAnn Suzich was promoted to vice president of Read more...
Pharma goes mad for biotech deals
One word: Biotech. As if acting on some wise elder's tip-off, Pharma got its biotech groove on in Read more...
ALSO NOTED: Novo Nordisk, Pfizer settle insulin suit; Perrigo gets OK for generic heartburn drug;
> Now that Pfizer has pulled Exubera off the market, Novo Nordisk has settled a patent lawsuit with the company over the inhaled insulin product. Novo Nordisk had alleged that Exubera was based on Read more...
ALSO NOTED: Korea fines pharma firms for kickbacks; Medco boosts profits 16 percent;
> Ten Korean drug makers were fined $22 million for illegal rebates to hospitals and wholesalers. Report > Read more...
SPOTLIGHT: Vaccine panel endorses FluMist for toddlers
MedImmune's FluMist was endorsed for children as young as 2 by the Advisory Committee on Immunization Practices, which advises government health officials. The inhaled flu vaccine was approved for Read more...
ALSO NOTED: Layoffs depress J&J profits; Canada OKs Pfizer HIV med;
> Pink slips cost money. Just ask Johnson & Johnson, which saw its third-quarter profits drop by 8 percent because of money spent cutting jobs. Read more...
Will Big Pharma buy Biogen Idec?
So, Big Pharma--you all want to make a deal with biotech. But who's most likely to step up to the plate for Biogen Idec? Analysts put the price tag at $25 billion to $30 billion, so only the Read more...
CDC: Plenty of flu vaccine to go around
You know flu season's coming up when the media starts chanting about flu vaccines and flu remedies. So break out the tissue and fluids, because three big flu stories hit the news today. First, good Read more...
| Press ReleasesPRESS RELEASE: Medimmune and Crucell announce collaboration Medimmune and Crucell announce collaboration to develop new antibodies for the treatment and prevention of hospital-acquired bacterial infection Gaithersburg, MD, USA and Leiden, The Netherlands - Read more... PRESS RELEASE: MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production GAITHERSBURG, Md., Sept. 24 -- MedImmune, Inc. announced today that it has Read more... PRESS RELEASE: MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R) FluMist Expected to Be Available Soon for 2007-2008 Season GAITHERSBURG, Md., Sept. 7 -- MedImmune announced today Read more... |
Get more MedImmune coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets